JP7166280B2 - 発作を抑制する組成物及び方法 - Google Patents

発作を抑制する組成物及び方法 Download PDF

Info

Publication number
JP7166280B2
JP7166280B2 JP2019554495A JP2019554495A JP7166280B2 JP 7166280 B2 JP7166280 B2 JP 7166280B2 JP 2019554495 A JP2019554495 A JP 2019554495A JP 2019554495 A JP2019554495 A JP 2019554495A JP 7166280 B2 JP7166280 B2 JP 7166280B2
Authority
JP
Japan
Prior art keywords
composition
mice
bacteria
parabacteroides
seizure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019554495A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502281A5 (cg-RX-API-DMAC7.html
JP2020502281A (ja
Inventor
シャオ，エレイン
ヤノ，ジェシカ
ヴォン，ヘレン
オルソン，クリスティーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2020502281A publication Critical patent/JP2020502281A/ja
Publication of JP2020502281A5 publication Critical patent/JP2020502281A5/ja
Application granted granted Critical
Publication of JP7166280B2 publication Critical patent/JP7166280B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dairy Products (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2019554495A 2016-12-20 2017-12-20 発作を抑制する組成物及び方法 Active JP7166280B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662436711P 2016-12-20 2016-12-20
US62/436,711 2016-12-20
US201762447992P 2017-01-19 2017-01-19
US62/447,992 2017-01-19
PCT/US2017/067548 WO2018119048A1 (en) 2016-12-20 2017-12-20 Compositions and methods for inhibiting seizures

Publications (3)

Publication Number Publication Date
JP2020502281A JP2020502281A (ja) 2020-01-23
JP2020502281A5 JP2020502281A5 (cg-RX-API-DMAC7.html) 2021-02-04
JP7166280B2 true JP7166280B2 (ja) 2022-11-07

Family

ID=62627881

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019554495A Active JP7166280B2 (ja) 2016-12-20 2017-12-20 発作を抑制する組成物及び方法

Country Status (7)

Country Link
US (3) US11129858B2 (cg-RX-API-DMAC7.html)
EP (1) EP3558329B1 (cg-RX-API-DMAC7.html)
JP (1) JP7166280B2 (cg-RX-API-DMAC7.html)
CN (2) CN119033822A (cg-RX-API-DMAC7.html)
AU (1) AU2017382197B2 (cg-RX-API-DMAC7.html)
CA (1) CA3047397A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018119048A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3558329B1 (en) 2016-12-20 2024-01-31 The Regents of The University of California Compositions and methods for inhibiting seizures
SG11201912105PA (en) * 2017-06-14 2020-01-30 4D Pharma Res Ltd Compositions comprising bacterial strains
WO2020058979A2 (en) * 2018-09-20 2020-03-26 Yeda Research And Development Co. Ltd. Methods of treating amyotrophic lateral sclerosis
WO2020069280A1 (en) * 2018-09-27 2020-04-02 Crestovo Holdings Llc Compositions and methods for treating epilepsy and related disorders
KR102340392B1 (ko) * 2018-10-08 2021-12-17 한국생명공학연구원 우울증의 예방 또는 치료 효과를 가지는 장내 미생물 및 이의 용도
CN110227085A (zh) * 2019-07-16 2019-09-13 江苏省中医院 Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用
US20230248782A1 (en) * 2020-06-12 2023-08-10 Morinaga Milk Industry Co., Ltd. Mitochondrial Function-Improving Composition
CN113367328B (zh) * 2021-06-11 2023-02-21 无锡市人民医院 一种调节肠道菌群和能量代谢的多阶段生酮饮食配方
WO2023001368A1 (en) * 2021-07-20 2023-01-26 Université Catholique de Louvain Prevention and/or treatment of reward dysregulation disorders
WO2023001934A1 (en) * 2021-07-20 2023-01-26 Université Catholique de Louvain Prevention and/or treatment of reward dysregulation disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016503418A (ja) 2012-11-19 2016-02-04 ウニベルシテ カソリーク デ ルーベン 代謝障害を処置するアッカーマンシアの使用
US20160143961A1 (en) 2014-11-25 2016-05-26 Epiva Biosciences, Inc. Probiotic and prebiotic compositions, and methods of use thereof for treatment and prevention of graft versus host disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
CA2940226A1 (en) * 2013-02-22 2014-08-28 The Regents Of The University Of California Compositions and methods for promoting growth of beneficial microbes to treat or prevent disease or prolong life
KR101445243B1 (ko) * 2014-03-28 2014-09-29 서울대학교산학협력단 장내 세균의 군집과 기능의 변화를 이용한 대사성 및 염증성 질환의 조기진단
EP3297727A1 (en) * 2015-05-21 2018-03-28 Yeda Research and Development Co. Ltd Bacterial populations for promoting health
CN114470009A (zh) 2015-05-22 2022-05-13 亚利桑那大学董事会 用于治疗自闭症谱系障碍及相关症状的方法
EP3558329B1 (en) 2016-12-20 2024-01-31 The Regents of The University of California Compositions and methods for inhibiting seizures
US20220184084A1 (en) 2019-03-18 2022-06-16 The Regents Of The University Of California Compositions and methods for treating cushing's disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016503418A (ja) 2012-11-19 2016-02-04 ウニベルシテ カソリーク デ ルーベン 代謝障害を処置するアッカーマンシアの使用
US20160143961A1 (en) 2014-11-25 2016-05-26 Epiva Biosciences, Inc. Probiotic and prebiotic compositions, and methods of use thereof for treatment and prevention of graft versus host disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Can. J. Infect. Dis. Med. Microbiol., (2016.11), 2016, Article.9032809
J. Mol. Endocrinal., (2017(Epub:2016.12.07)), 58, [1], p.1-14
Mol. Autism, (2016.09), 7, [1], Article.37

Also Published As

Publication number Publication date
EP3558329A1 (en) 2019-10-30
EP3558329C0 (en) 2024-01-31
EP3558329A4 (en) 2020-07-22
CN119033822A (zh) 2024-11-29
WO2018119048A1 (en) 2018-06-28
AU2017382197B2 (en) 2022-12-01
CN110325196A (zh) 2019-10-11
US20200384037A1 (en) 2020-12-10
US20240238350A1 (en) 2024-07-18
CA3047397A1 (en) 2018-06-28
US11883441B2 (en) 2024-01-30
AU2017382197A1 (en) 2019-07-04
EP3558329B1 (en) 2024-01-31
US20220184144A1 (en) 2022-06-16
CN110325196B (zh) 2024-08-27
JP2020502281A (ja) 2020-01-23
US12364717B2 (en) 2025-07-22
US11129858B2 (en) 2021-09-28

Similar Documents

Publication Publication Date Title
JP7166280B2 (ja) 発作を抑制する組成物及び方法
US12292445B2 (en) Methods of selecting subjects for treatment with metabolomic modulators
US20210128641A1 (en) Compositions and methods for treating skin and mucous membrane diseases
RU2669800C2 (ru) Способы лечения воспаления, аутоиммунных расстройств и боли
EP3536328B1 (en) Food or beverage product, or probiotic composition, comprising lactobacillus johnsonii 456
JP6082596B2 (ja) アルツハイマー病と加齢脳に対する補充療法
JP2022549139A (ja) 代謝性疾患および障害を治療するための方法およびプロバイオティック組成物
BR112019026677A2 (pt) composições compreendendo cepas bacterianas
JP7013238B2 (ja) 筋脂肪化抑制用組成物
EP4108260A1 (en) Composition for alleviating pulmonary hypertension, method for predicting prognosis of pulmonary hypertension, method for assisting in determining severity of pulmonary hypertension, and method for assisting in diagnosing pulmonary hypertension
EP3965820A1 (en) Compositions and methods for promoting healthy neural development in an unborn baby
EP4066844A1 (en) Compositions comprising anaerostipes hadrus
TW201907925A (zh) N-取代之甘胺酸化合物的鋰鹽及其用途
WO2025038777A2 (en) Probiotics and methods to reduce appetite
WO2020251794A2 (en) Compositions and methods for modulating cognitive behavior
US20250025516A1 (en) Compositions and methods for inhibiting seizures
EP4620479A1 (en) Postbiotic preparation comprising pediococcus acidilactici for preventing or treating obesity
JP7738992B2 (ja) アルツハイマー病様症状緩和剤
JP2025143412A (ja) オキシカム系化合物を含む筋疾患の予防または治療用組成物
KR20240040059A (ko) 불포화 하이드록삼산 유도체 및 암모니아 연관 질환 또는 장애의 치료 및 예방을 위한 이의 용도
WO2026006209A1 (en) Compositions including n-acetyl-d-glucosamine (glcnac) as a prebiotic agent against multiple oral diseases
WO2023094644A1 (fr) Utilisation d'un muramyl peptide dans le traitement des retards de croissance squelettique
WO2025250747A1 (en) Gut microbiome-derived metabolite(s) promote skeletal muscle adaptation to exercise

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190903

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20190903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220524

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220927

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221025

R150 Certificate of patent or registration of utility model

Ref document number: 7166280

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250